Sanofi (SNY) Other Non-Current Assets (2009 - 2026)
Sanofi (SNY) posted Other Non-Current Assets of $5.5 billion for Q2 2026, up 639.86% sequentially from $743.4 million in Q1 2026, and up 18.25% YoY from $4.7 billion in Q2 2025.
Sanofi (SNY) Other Non-Current Assets (2009 - 2026) Analysis & Trends
Sanofi has reported Other Non-Current Assets for 18 years, with the latest figure at $5.5 billion in Q2 2026.
- Quarterly Other Non-Current Assets rose 18.25% year-over-year to $5.5 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $5.5 billion (up 18.25% YoY) and the FY2025 annual result came in at $5.1 billion, up 26.67% from the prior year.
- Other Non-Current Assets grew to $5.5 billion in Q2 2026 per SNY's latest filing, from $743.4 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $14.4 billion in Q1 2025 and troughed at $161.3 million in Q3 2025.
- A 5-year average of $4.3 billion and a median of $3.6 billion in 2022 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2025 and 2026: Other Non-Current Assets grew 29.59% in 2025, then tumbled 94.85% in 2026.
- Over 5 years, Other Non-Current Assets stood at $3.2 billion in 2022, then rose by 9.65% to $3.5 billion in 2023, then advanced by 15.83% to $4.0 billion in 2024, then gained by 26.67% to $5.1 billion in 2025, then advanced by 8.28% to $5.5 billion in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $5.5 billion, $743.4 million, and $5.1 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 14.27 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 10.73 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 19.60 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.93 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 12.98 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 4.75 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 9.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 3.56 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 5.50 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.50 Bn |
| Mar 31, 2026 | 743.42 Mn |
| Dec 31, 2025 | 5.08 Bn |
| Sep 30, 2025 | 161.33 Mn |
| Jun 30, 2025 | 4.65 Bn |
| Mar 31, 2025 | 14.44 Bn |
| Dec 31, 2024 | 4.01 Bn |
| Jun 30, 2024 | 3.59 Bn |
| Dec 31, 2023 | 3.46 Bn |
| Jun 30, 2023 | 3.26 Bn |
| Dec 31, 2022 | 3.16 Bn |
| Jun 30, 2022 | 3.53 Bn |
| Dec 31, 2021 | 3.58 Bn |
| Jun 30, 2021 | 3.25 Bn |
| Dec 31, 2020 | 3.26 Bn |
| Jun 30, 2020 | 3.34 Bn |
| Dec 31, 2019 | 110,688.77 |
| Jun 30, 2019 | 2.54 Bn |
| Dec 31, 2018 | 3.21 Bn |
| Sep 30, 2018 | 1.16 Mn |